MedDataX Logo

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

NCT02284139 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-04-23

No results posted yet for this study

Summary

The efficacy of the epidermal growth factor receptor (EGFR) inhibitors have been demonstrated in patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal cancer (CRC). Dermatological reactions can cause significant physical and psycho-social discomfort to patients. In the present study, the investigators evaluated the effect of epidermal growth factor (EGF) ointment on EGFR inhibitor-related skin side effects (ERSEs).

Conditions

  • Non-small Cell Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer

Interventions

DRUG

Arm EGF ointment 1ppm

EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day

DRUG

Arm EGF ointment 20 ppm

EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day

DRUG

Arm Placebos

EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day

Sponsors & Collaborators

  • Dong-A University Hospital

    lead OTHER

Principal Investigators

  • SUNG YONG OH, M.D. · Dong-A University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02284139 on ClinicalTrials.gov